Moderna getting ripe: CMP 28While short-term indicators show some bullish signs, the medium- and long-term trends remain bearish.
The stock might remain range-bound for a couple of weeks before any uptrend, which will only be confirmed once it breaks the parallel line before making a fresh upmove. Also, $27.5 can be taken as
−0.330 USD
−3.16 B USD
2.87 B USD
About Moderna, Inc.
Sector
Industry
CEO
Stéphane Bancel
Website
Headquarters
Cambridge
Founded
2010
ISIN
AR0666228538
FIGI
BBG01MDJMR28
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.
Related stocks
Moderna - Long
Moderna is showing signs of recovery. Has made a base in the weekly and daily charts as marked by sky blue and white horizontal lines.
Immediate target $128.
However, there are another 3 and half days left for the end of the week. Smart recovery is on the cards, next week.
I am not a register
Sunday Prep 9/5 - $MRNA Looking good for a move back to ATHThe setup is there to take this name back to ATHs. Technically needs over 418.44 to confirm the long trigger, but don’t think that’s going to be a problem if the momentum continues.
Will need to see some retests of key levels hold before being interested. First area of interest would be the rece
See all ideas
Curated watchlists where MRNAC is featured.